Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Vir Biotechnology (NASDAQ:VIR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Profitability
This table compares Cardiff Oncology and Vir Biotechnology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiff Oncology | -6,238.17% | -73.97% | -60.40% |
| Vir Biotechnology | -678.40% | -36.71% | -31.00% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Cardiff Oncology and Vir Biotechnology, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiff Oncology | 0 | 0 | 3 | 0 | 3.00 |
| Vir Biotechnology | 0 | 1 | 5 | 0 | 2.83 |
Institutional & Insider Ownership
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 7.6% of Cardiff Oncology shares are held by company insiders. Comparatively, 15.6% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Cardiff Oncology and Vir Biotechnology”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiff Oncology | $688,000.00 | 338.91 | -$41.44 million | ($0.94) | -4.85 |
| Vir Biotechnology | $86.18 million | 15.13 | -$615.06 million | ($3.92) | -2.42 |
Cardiff Oncology has higher earnings, but lower revenue than Vir Biotechnology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Cardiff Oncology has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.
Summary
Vir Biotechnology beats Cardiff Oncology on 9 of the 14 factors compared between the two stocks.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
About Vir Biotechnology
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
